

Product Datasheet

Selpercatinib

Catalog No. **BP-01975** · CAS **2152628-33-4** · Form **free base** · Physical state **other** · Version **1.0** · Revision **2026-09-03**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target RET	Research area Cancer
----------------------	--------------------------------

Molecular formula **C₂₉H₃₁N₇O₃**

Molecular weight **525.6015**

STRUCTURE



DESCRIPTION

Selpercatinib (LOXO-292) is a RET kinase inhibitor.

BIOLOGICAL ACTIVITY

In Vivo

Selpercatinib (LOXO-292; 10 mg/kg; i.g.; for 0-2 h) has good pharmacokinetics after oral gavage in FVB/NRj mice.

SOLUBILITY

Soluble in DMSO

REFERENCES

[1]. Şentürk R, et, al. Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Jun 15;1147:122131.

[2]. Steven W. Andrews, et al. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors. WO2018071447A1.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.